High cholesterol is one of the most common and manageable risk factors for heart disease. Millions of adults are prescribed cholesterol-lowering drugs to reduce low-density lipoprotein (LDL) ...
Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention VESALIUS-CV Subgroup Findings Reinforce Benefit of Earlier Initiation of Repatha ...
THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to include ...
It’s not necessarily a bad thing. A cardiologist weighs in.